Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The pinch at the pump continues on - 2NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- 3Newly identified species of Tanzanian tree toad leapfrog the tadpole stage and give birth to toadlets
- 4Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- 5Southern Californians, your health insurance costs could rise in 2026
- Computerized Moderation: Tracking down Equilibrium in the Advanced Age
- Vote In favor of Your Favored Shades
- Why haven’t humans been back to the moon in over 50 years?
- Ukrainian foreign minister appeals for funds for drones
- NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
- 'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- World's oldest known tortoise still very much alive despite rumor to the contrary
- The Force of Care: Living with Goal
- First SpaceX booster for upgraded Starship fails during test in Texas
